Haleon plc (LON:HLN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 34.52B |
| Revenue (ttm) | 11.23B |
| Net Income (ttm) | 1.44B |
| Shares Out | 9.04B |
| EPS (ttm) | 0.16 |
| PE Ratio | 24.34 |
| Forward PE | 20.12 |
| Dividend | 0.07 (1.73%) |
| Ex-Dividend Date | Apr 24, 2025 |
| Volume | 20,830,348 |
| Average Volume | 33,782,661 |
| Open | 381.80 |
| Previous Close | 382.20 |
| Day's Range | 378.70 - 383.10 |
| 52-Week Range | 319.20 - 417.70 |
| Beta | 0.23 |
| RSI | 41.63 |
| Earnings Date | Feb 27, 2025 |
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprisi... [Read more]
Financial Performance
In 2024, Haleon's revenue was 11.23 billion, a decrease of -0.61% compared to the previous year's 11.30 billion. Earnings were 1.44 billion, an increase of 37.46%.
Financial StatementsNews
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off
Sensodyne toothpaste maker Haleon now an independent company after Pfizer sells stake
Shares in the consumer health group - originally a joint venture between Pfizer and GSK - are up nearly a fifth since it joined the stock market in 2022.
Pfizer exits Haleon stake after $3.2B share sale
Pfizer offloads final shares in Sensodyne maker Haleon
Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer.
Pfizer Sells Remaining Stake in Haleon for $3.25 Billion
Pfizer Sells Remaining Stake in Haleon for $3.25 Billion
Pfizer sells entire Haleon stake for $3.24 billion
Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for t...
FTSE 100 Live 19 March: Index steady after US selling, Pfizer makes £2.5bn Haleon exit
Pfizer to sell remaining stake in Haleon
Pfizer to dispose of entire Haleon stake
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, wit...
Haleon: Growing Profits And Dividend
Haleon's dividend grew 10% and is well-covered by FCF, but the 1.6% yield is less attractive compared to peers. See why I rate HLN stock a hold.
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
London-based consumer healthcare group Haleon Plc (NYSE: HLN) stock is trading lower on Thursday. Haleon, GSK Plc’s (NYSE: GSK) spun off, reported revenue of 11.23 billion pounds (US$14.19 billion) ...
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday.
Haleon CEO: We're relatively low-exposed to tariffs
Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results
Haleon plc (HLN) Q4 2024 Earnings Call Transcript
Haleon plc 2024 Q4 - Results - Earnings Call Presentation
Haleon CEO: We're relatively low-exposed to tariffs
Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results
Haleon Non-GAAP EPS of 17.90p, revenue of £11.23B; initiates FY25 and medium term guidance
Haleon Expects Further Growth After Profit Rises
Earnings Scheduled For February 27, 2025
Companies Reporting Before The Bell • Hafnia (NYSE: HAFN) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ: ARGX) is projected to report quarterly earnings at $1.06 per share...
Haleon to invest $54 mln in US R&D centre to boost product innovation
Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovation...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
On Thursday, Dr. Reddy's Laboratories Ltd (NYSE: RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginall...
Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
Pfizer Sells Stake in Haleon, Reduces Holding to 7.3%
Pfizer Sells Stake in Haleon, Reduces Holding to 7.3%
Pfizer Sells Stake in Haleon for $3.05 Billion
Pfizer Sells Stake in Haleon for $3.05 Billion